Can peripheral blood γδ T cells predict osteonecrosis of the jaw? An immunological perspective on the adverse drug effects of aminobisphosphonate therapy

Journal of Bone and Mineral Research

Volumn 28, Issue 4, 2013, Pages 728-735

  Kalyan, Shirin ^a   Quabius, Elgar Susanne ^a   Wiltfang, Jörg ^a   Mönig, Heiner ^a   Kabelitz, Dieter ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

T cells; bisphosphonate therapy; osteonecrosis of the jaw; osteoporosis

Indexed keywords

ALENDRONIC ACID; IBANDRONIC ACID; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; LYMPHOCYTE ANTIGEN RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD; CELL FATE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG EFFECT; FEMALE; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNE SYSTEM; JAW OSTEONECROSIS; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; OSTEOPOROSIS; PROGNOSIS; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; VGAMMA9VDELTA2 T CELL; ADAPTIVE IMMUNITY; CELL SIZE; COHORT ANALYSIS; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE COUNT; MIDDLE AGED; PHENOTYPE; TIME FACTOR; VERY ELDERLY;

ADAPTIVE IMMUNITY; AGED; AGED, 80 AND OVER; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; CELL SIZE; COHORT STUDIES; DIPHOSPHONATES; FEMALE; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; OSTEOPOROSIS; PHENOTYPE; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; TIME FACTORS;

EID: 84875293817     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1769     Document Type: Article

References (32)

1. Wimalawansa SJ., Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opin Drug Safety. 2008; 7: 491-512.
2. Roelofs AJ, Thompson K, Gordon S, Rogers MJ., Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006; 12: 6222s-30s.
3. Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G, Bonneville M, Fournie JJ., Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science. 1994; 264: 267-70.
4. Kunzmann V, Bauer E, Wilhelm M., Gamma/delta T-cell stimulation by pamidronate. N Engl J Med. 1999; 340: 737-8.
5. Migliorati CA, Siegel MA, Elting LS., Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol. 2006; 7: 508-14.
6. Reid IR., Osteonecrosis of the jaw: who gets it, and why?. Bone. 2009; 44: 4-10.
7. Edwards BJ, Gounder M, McKoy JM, Boyd I, Farrugia M, Migliorati C, Marx R, Ruggiero S, Dimopoulos M, Raisch DW, Singhal S, Carson K, Obadina E, Trifilio S, West D, Mehta J, Bennett CL., Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol. 2008; 9: 1166-72.
8. Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW., Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg. 2008; 66: 767-75.
9. Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, Thompson K., Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol. 2009; 144: 245-50.
10. Roelofs AJ, Coxon FP, Ebetino FH, Lundy MW, Henneman ZJ, Nancollas GH, Sun S, Blazewska KM, Bala JL, Kashemirov BA, Khalid AB, McKenna CE, Rogers MJ., Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res. 2010; 25: 606-16.
11. Miyagawa F, Tanaka Y, Yamashita S, Minato N., Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gamma delta T cells by aminobisphosphonate antigen. J Immunol. 2001; 166: 5508-14.
12. Wang L, Das H, Kamath A, Li L, Bukowski JF., Human V gamma 2V delta 2 T cells augment migration-inhibitory factor secretion and counteract the inhibitory effect of glucocorticoids on IL-1 beta and TNF-alpha production. J Immunol. 2002; 168: 4889-96.
13. Lahn M, Kanehiro A, Takeda K, Konowal A, O'Brien RL, Gelfand EW, Born WK., gammadelta T cells as regulators of airway hyperresponsiveness. Int Arch Allergy Immunol. 2001; 125: 203-10.
14. Kalyan S, Chow AW., Human peripheral gammadelta T cells potentiate the early proinflammatory cytokine response to staphylococcal toxic shock syndrome toxin-1. J Infect Dis. 2004; 189: 1892-6.
15. Fu YX, Roark CE, Kelly K, Drevets D, Campbell P, O'Brien R, Born W., Immune protection and control of inflammatory tissue necrosis by gamma delta T cells. J Immunol. 1994; 153: 3101-15.
16. Li Z, Burns AR, Rumbaut RE, Smith CW., Gamma delta T cells are necessary for platelet and neutrophil accumulation in limbal vessels and efficient epithelial repair after corneal abrasion. Am J Pathol. 2007; 171: 838-45.
17. Carding SR, Egan PJ., The importance of gamma delta T cells in the resolution of pathogen-induced inflammatory immune responses. Immunol Rev. 2000; 173: 98-108.
18. Egan PJ, Carding SR., Downmodulation of the inflammatory response to bacterial infection by gammadelta T cells cytotoxic for activated macrophages. J Exp Med. 2000; 191: 2145-58.
19. Havran WL., A role for epithelial gammadelta T cells in tissue repair. Immunol Res. 2000; 21: 63-9.
20. Kalyan S, Wesch D, Kabelitz D., Aminobisphosphonates and Toll-like receptor ligands: recruiting Vgamma9Vdelta2 T cells for the treatment of hematologic malignancy. Curr Med Chem. 2011; 18: 5206-16.
21. Kabelitz D., Human gammadelta T lymphocytes for immunotherapeutic strategies against cancer. F1000 Med Rep. 2010; 2: 45.
22. Gertner-Dardenne J, Bonnafous C, Bezombes C, Capietto AH, Scaglione V, Ingoure S, Cendron D, Gross E, Lepage JF, Quillet-Mary A, Ysebaert L, Laurent G, Sicard H, Fournie JJ., Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood. 2009; 113: 4875-4.
23. Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, La Mendola C, Guggino G, D'Asaro M, Orlando V, Scarpa F, Roberts A, Caccamo N, Stassi G, Dieli F, Hayday AC., In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol. 2010; 161: 290-7.
24. Marx RE, Cillo JE Jr, Ulloa JJ., Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007; 65: 2397-410.
25. Palaska PK, Cartsos V, Zavras AI., Bisphosphonates and time to osteonecrosis development. Oncologist. 2009; 14: 1154-66.
26. Rossini M, Adami S, Viapiana O, Ortolani R, Vella A, Fracassi E, Gatti D., Circulating gammadelta T cells and the risk of acute-phase response after zoledronic acid administration. J Bone Miner Res. 2011 Sep 28 [Epub ahead of print].
27. Weinstein RS, Roberson PK, Manolagas SC., Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009; 360: 53-62.
28. Jameson J, Ugarte K, Chen N, Yachi P, Fuchs E, Boismenu R, Havran WL., A role for skin gammadelta T cells in wound repair. Science. 2002; 296: 747-9.
29. Workalemahu G, Foerster M, Kroegel C, Braun RK., Human gamma delta-T lymphocytes express and synthesize connective tissue growth factor: effect of IL-15 and TGF-beta 1 and comparison with alpha,beta-T lymphocytes. J Immunol. 2003; 170: 153-7.
30. Gan YH, Wallace M, Malkovsky M., Fas-dependent, activation-induced cell death of gammadelta cells. J Biol Regul Homeost Agents. 2001; 15: 277-85.
31. Enders PJ, Yin C, Martini F, Evans PS, Propp N, Poccia F, Pauza CD., HIV-mediated gammadelta T cell depletion is specific for Vgamma2+ cells expressing the Jgamma1.2 segment. AIDS Res Hum Retroviruses. 2003; 19: 21-9.
32. Mary-Krause M, Billaud E, Poizot-Martin I, Simon A, Dhiver C, Dupont C, Salmon D, Roudiere L, Costagliola D., Clinical Epidemiology Group of the French Hospital Database. Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy. AIDS. 2006; 20: 1627-35.